Cited by

• Six and eight weeks injection frequencies of bevacizumab are non-inferior to the current four weeks injection frequency for quality of life in neovascular age-related macular degeneration: a randomized controlled trial.

  Visser MS, Amarakoon S, Missotten T, Timman R, Busschbach JJV. Visser MS, et al. Qual Life Res. 2020 Dec;29(12):3305-3313. doi: 10.1007/s11136-020-02580-9. Epub 2020 Jul 14. Qual Life Res. 2020. PMID: 32666333 Free PMC article. Clinical Trial.
• Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a Meta-analysis.

  Wang WJ, Chen J, Zhang XL, Yao M, Liu XY, Zhou Q, Qu YX. Wang WJ, et al. Int J Ophthalmol. 2015 Feb 18;8(1):138-47. doi: 10.3980/j.issn.2222-3959.2015.01.26. eCollection 2015. Int J Ophthalmol. 2015. PMID: 25709924 Free PMC article.
• Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8).

  Horner F, Lip PL, Clark H, Chavan R, Sarmad A, Mushtaq B. Horner F, et al. Clin Ophthalmol. 2019 Dec 12;13:2461-2467. doi: 10.2147/OPTH.S218378. eCollection 2019. Clin Ophthalmol. 2019. PMID: 31849444 Free PMC article.
• Hypoxic drive caused type 3 neovascularization in a preclinical model of exudative age-related macular degeneration.

  Zhang L, Cui X, Han Y, Park KS, Gao X, Zhang X, Yuan Z, Hu Y, Hsu CW, Li X, Bassuk AG, Mahajan VB, Wang NK, Tsang SH. Zhang L, et al. Hum Mol Genet. 2019 Oct 15;28(20):3475-3485. doi: 10.1093/hmg/ddz159. Hum Mol Genet. 2019. PMID: 31518400 Free PMC article.
• Hyperreflective foci in predicting the treatment outcome of antivascular endothelial growth factor in neovascular age-related macular degeneration.

  Hsia Y, Yang CH, Hsieh YT, Yang CM, Ho TC, Lai TT. Hsia Y, et al. Graefes Arch Clin Exp Ophthalmol. 2020 Feb;258(2):273-280. doi: 10.1007/s00417-019-04546-1. Epub 2019 Dec 11. Graefes Arch Clin Exp Ophthalmol. 2020. PMID: 31828425